Haematological Cancer Patients, Invasive Aspergillosis, Voriconazole
Conditions
Keywords
voriconazole, pharmacogenetics, pharmacokinetics, therapeutic drug monitoring
Brief summary
Hypothesis: A pharmacogenetic score integrating both CYP3A genotypes could be influence initial trough voriconazole plasma concentrations and thus useful to adapt a priori voriconazole dosing in order to get adequate voriconazole exposure as possible after starting treatment. Main Objective: To determine predictive value of a combined pharmacogenetic score on onset of trough voriconazole plasma concentration inferior than lower therapeutic target.
Detailed description
Voriconazole (VRC), the gold-standard treatment of invasive aspergillosis is characterized by variables and nonlinear pharmacokinetics, causing many under- or over-dosing. A link exist between trough plasma concentrations (Cmin) of VRC and effectiveness but also its toxicity. Thus the longitudinal therapeutic drug monitoring of VRC is now recommended with a therapeutic range between 1 and 5 mg/L. The pharmacokinetic variability of VRC is in part explained by its metabolism, mainly dependent on cytochrome P 450 (CYP), particularly CYP2C19, 3A4, 3A5; all these CYP exhibiting genetic polymorphisms. The authors, recently shown, and for the first time , in a retrospective study conducted in 29 patients allogeneic hematopoietic stem cell that initial VRC Cmin adjusted the dose was not only influenced by the route of administration but also by a pharmacogenetics score whose determination is to assign each genotype CYP2C19 and CYP3A a score expressed in a arbitrary units. The combined pharmacogenetic score was strongly correlated with the original Cmin (r= -0.748; p = 0.002) and was the only independent predictor of initial Cmin (after adjusting the dose and the route of administration). In addition, none of the patients having a genetic score \<2 (ie metabolizing capacity of reduced VRC) did not show an initial Cmin below 1 mg/L, while the initial Cmin was below this threshold efficiency in 47% of patients with a genetic score \>2. The aim of this new study is to confirm the impact of the pharmacogenetic score on the initial VRC Cmin over a larger prospective cohort of 60 adult patients with onco-hematological diseases.
Interventions
None listed
Sponsors
University Hospital, Grenoble
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients suffering from haematological cancer
Exclusion criteria
* less than 18-years old
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of initial voriconazole trough plasma concentration in the therapeutic range (1-4mg/l) | concentration measured between 5 to 10 days after voriconazole treatment initiation | Initial voriconazole trough plasma concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| number of patients with therapeutic success | 3 months after voriconazole therapy initiation | treatment outcome determined 3 months after voriconazole initiation (failure, stable response, success) |
| initial voriconazole trough plasma concentrations adjusted on the dose | concentration measured between 5 to 10 days after voriconazole treatment initiation | Initial voriconazole trough plasma concentration |
| number of patients with adverse effects | duration of voriconazole treatment (maximum length of follow-up : 3 months) | adverse effects include neurological disorders such as visual disturbance and/or hallucinations and hepatotoxicity (evaluated by ALAT/ASAT, bilirubin and γ-GT levels), |
Countries
France
Outcome results
None listed